Curcumin in the prevention of cisplatin-induced acute nephrotoxicity
- Conditions
- ephrotoxicity.Other acute kidney failureN17.8
- Registration Number
- IRCT20180722040556N8
- Lead Sponsor
- Esfahan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 100
Creatinine Clearance higher than 45 mL/min based on CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
The patient who will have enough compliance and ability to take curcumin orally.
All adult cancer 's patients who will receive a regimen contains cisplatin (with the usual recommended dose between 50-100 mg / m2 )
Patients with active infection or symptoms of sepsis.
Patients who have received nephrotoxic drugs such as aminoglycoside, amphotericin, vancomycin, colistin, media contrast, calcineurin inhibitors or Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) for the past 72 hours.
Patients who are taking ifosfamide in their chemotherapy regimen
Patients who are taking fluvoxamine, anagrelide, or hydroxy progesterone in their treatment regimen.
Patients who may experience complications or allergic reactions to curcumin during treatment.
Patients who had a history of acute kidney injury ( AKI ) before entering the study.
Patients with bilirubin above 2 mg / dl or liver enzymes above 2.5 times the normal level.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of cisplatin-induced renal injury according to cheng in Glomerular Filtration Rate (GFR). Timepoint: Measurement of BUN, creatinine, in urine and serum at the time of the previous day, a day and five days after treatment with Cisplatin. Method of measurement: Measurement of urine and serum values by electrolyte analyzer and fordata analysis using Statistical Package for Social Sciences (SPSS).
- Secondary Outcome Measures
Name Time Method